Quetglas E G, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese Silvio
Project Strategy & Science, Grünenthal GmbH, Aachen, Germany.
Eur J Clin Pharmacol. 2015 Jul;71(7):773-99. doi: 10.1007/s00228-015-1862-7. Epub 2015 May 27.
The following review is a compilation of the recent advances and knowledge on the behaviour of the most frequently used compounds to treat inflammatory bowel disease in an organism.
It considers clinical aspects of each entity and the pharmacokinetic/pharmacodynamic relationship supported by the use of plasma monitoring, tissue concentrations, and certain aspects derived from pharmacogenetics.
以下综述汇编了关于治疗机体炎症性肠病最常用化合物行为的最新进展和知识。
它考虑了每个实体的临床方面以及通过血浆监测、组织浓度和药物遗传学某些方面所支持的药代动力学/药效学关系。